Does USTEKINUMAB Cause Maternal exposure timing unspecified? 184 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 184 reports of Maternal exposure timing unspecified have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.2% of all adverse event reports for USTEKINUMAB.
184
Reports of Maternal exposure timing unspecified with USTEKINUMAB
0.2%
of all USTEKINUMAB reports
158
Deaths
173
Hospitalizations
How Dangerous Is Maternal exposure timing unspecified From USTEKINUMAB?
Of the 184 reports, 158 (85.9%) resulted in death, 173 (94.0%) required hospitalization, and 171 (92.9%) were considered life-threatening.
Is Maternal exposure timing unspecified Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 184 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Maternal exposure timing unspecified?
RITUXIMAB (402)
METHOTREXATE (350)
ADALIMUMAB (343)
DICLOFENAC (331)
TOCILIZUMAB (327)
HYDROXYCHLOROQUINE (309)
FOLIC ACID (304)
INFLIXIMAB (303)
LEFLUNOMIDE (302)
SECUKINUMAB (301)
Which USTEKINUMAB Alternatives Have Lower Maternal exposure timing unspecified Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE